KYNTRA BIO, INC. (KYNB) Total liabilities 2016–2025
KYNTRA BIO, INC. (KYNB) total liabilities at each fiscal year-end, per SEC filings.
$115.1MFY2025 · since FY2016: $294.4M → $115.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $115.1M | -71.1% |
| FY2024 | $398.2M | -32.0% |
| FY2023 | $585.7M | -4.2% |
| FY2022 | $611.6M | +12.3% |
| FY2021 | $544.7M | +41.3% |
| FY2020 | $385.4M | +19.7% |
| FY2019 | $322.0M | -8.6% |
| FY2018 | $352.1M | +0.3% |
| FY2017 | $350.9M | +19.2% |
| FY2016 | $294.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More KYNB financial trends
KYNB RevenueKYNB Net incomeKYNB Net marginKYNB Gross profitKYNB Gross marginKYNB Operating incomeKYNB Operating marginKYNB Operating cash flowKYNB Free cash flowKYNB Capital expendituresKYNB Return on equityKYNB Stock buybacksKYNB Dividends paidKYNB Total assetsKYNB Shareholders’ equityKYNB overview →